

University of Groningen

**Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients**

van Breeschoten, Jesper; Wouters, Michel W. J. M.; Hilarius, Doranne L.; Haanen, John B.; Blank, Christian U.; Aarts, Maureen J. B.; van den Bergmortel, Franchette W. P. J.; de Groot, Jan-Willem B.; Hospers, Geke A. P.; Kapiteijn, Ellen

*Published in:*  
British Journal of Cancer

*DOI:*  
[10.1038/s41416-022-01772-z](https://doi.org/10.1038/s41416-022-01772-z)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2022

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Bergmortel, F. W. P. J., de Groot, J-W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokk, W. A. M., ten Tije, B-J. J., van der Veldt, A. A. M., Vreugdenhil, A., Boers-Sonderen, M. J., & van den Eertwegh, A. J. M. (2022). Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022). *British Journal of Cancer*, 126(9), 1362. <https://doi.org/10.1038/s41416-022-01772-z>

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.


**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## CORRECTION



# Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten, Michel W. J. M. Wouters, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jan-Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Karijn P. M. Suijkerbuijk, Willeke A. M. Blokx, Bert-Jan J. ten Tije, Astrid A. M. van der Veldt , Art Vreugdenhil, Marye J. Boers-Sonderen and Alfonsus J. M. van den Eertwegh

© The Author(s), under exclusive licence to Springer Nature Limited 2022

*British Journal of Cancer* (2022) 126:1362; <https://doi.org/10.1038/s41416-022-01772-z>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-020-01229-1>, published online 26 January 2021

The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional

Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.